NCT06517953

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine, GASTO-10114)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.

Conditions

• Non-small Cell Lung Cancer Metastatic
• EGFR G719X
• EGFR L861Q
• EGFR S768I

Interventions

Type	Name	Description
DRUG	Icotinib	An orally first-generation EGFR inhibitior.
DRUG	Befotertinib	An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.

Timeline

• Start date: 2024-07-17
• Primary completion: 2026-07-30
• Completion: 2027-12-24
• First posted: 2024-07-24
• Last updated: 2024-07-25

Locations

1 site across 1 country: China